Mosquirix, the pioneer drug for malaria is set to be released for public use, but the World Health Organization is not in favor of that idea. Experts said there should be more studies of the new malaria vaccine before it is put into widespread use.
Just this year, an estimated 214 million new cases of malaria was reported, with death totaling to 438,000. According to Abramson, there is no question about giving the drug; the real question is how they will give the doses of the shots when they don't even have a real interaction with the child. This approach is not only happening to malaria but to other major common infectious diseases too which involves very different people from all over the world. Patients needing the vaccine grows in number as day pass.
A spokeswoman cleared that were more or less 5,000 blood samples taken from the participants of the study which is already in the 3rd phase of the clinical testing for the vaccine. She also said that this single study is not big enough to provide concrete evidence for how RTS, S should be disposed.
The researchers in the study made a very important discovery through their collective survey of genetic variability in CS; they found that the vaccine is somewhat more effective at preventing malaria in children infected with parasites having matching alleles than in those who host parasites having no match in alleles. GlaxoSmithKline (GSK) scientists originally designed the vaccine in 1987; however, the development of the vaccine is now being led by a public-private partnership between two companies, GSK and PATH Malaria Vaccine Initiative.
The study highlights how a complete and detailed list of the genetic diversity of important pathogens could inform the design of a strong and effective vaccine. However, even if the CS protein is genetically different, meaning that it has variations, the RTS, S vaccine only has one.
